JP2023524288A - チロシナーゼ媒介部位特異的タンパク質コンジュゲーションのためのシステム及び方法 - Google Patents

チロシナーゼ媒介部位特異的タンパク質コンジュゲーションのためのシステム及び方法 Download PDF

Info

Publication number
JP2023524288A
JP2023524288A JP2022567076A JP2022567076A JP2023524288A JP 2023524288 A JP2023524288 A JP 2023524288A JP 2022567076 A JP2022567076 A JP 2022567076A JP 2022567076 A JP2022567076 A JP 2022567076A JP 2023524288 A JP2023524288 A JP 2023524288A
Authority
JP
Japan
Prior art keywords
tco
composition
functionalized
protein
quinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524288A5 (https=
Inventor
アデル マームード エルソーリー，
パトリック グウィン ホルダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023524288A publication Critical patent/JP2023524288A/ja
Publication of JP2023524288A5 publication Critical patent/JP2023524288A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022567076A 2020-05-05 2021-05-05 チロシナーゼ媒介部位特異的タンパク質コンジュゲーションのためのシステム及び方法 Pending JP2023524288A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020405P 2020-05-05 2020-05-05
US63/020,405 2020-05-05
PCT/US2021/030905 WO2021226247A1 (en) 2020-05-05 2021-05-05 Systems and methods for tyrosinase-mediated site-specific protein conjugation

Publications (2)

Publication Number Publication Date
JP2023524288A true JP2023524288A (ja) 2023-06-09
JP2023524288A5 JP2023524288A5 (https=) 2024-05-15

Family

ID=76160021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567076A Pending JP2023524288A (ja) 2020-05-05 2021-05-05 チロシナーゼ媒介部位特異的タンパク質コンジュゲーションのためのシステム及び方法

Country Status (7)

Country Link
US (1) US20230192760A1 (https=)
EP (1) EP4146665A1 (https=)
JP (1) JP2023524288A (https=)
CN (1) CN115551875A (https=)
AR (1) AR122020A1 (https=)
TW (1) TW202207988A (https=)
WO (1) WO2021226247A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119731192A (zh) * 2022-10-14 2025-03-28 香港中文大学 免疫球蛋白的位点特异性酪氨酸修饰
EP4653020A1 (en) * 2023-01-19 2025-11-26 Shanghai Shengdi Pharmaceutical Co., Ltd Tyrosinase-mediated protein site-specific conjugation and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504507A (ja) * 2007-11-21 2011-02-10 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アルキン類及び１，３−双極子機能性化合物とアルキン類を反応させる方法
JP2015525575A (ja) * 2012-08-08 2015-09-07 アプライズ バイオ， インコーポレイテッド 細胞中の複数のエピトープを同定するためのダイナミックレンジを高めること
EP2974744A1 (en) * 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
CN101048506B (zh) 2004-10-27 2013-06-26 斯克利普斯研究院 体内掺入非天然氨基酸的正交翻译组分
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
EP3424538A1 (en) * 2017-07-06 2019-01-09 Centre National De La Recherche Scientifique Bioconjugates with a controlled degree of conjugation, their process of preparation, and the reagents for their preparation
CA3099421C (en) * 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B.V. COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504507A (ja) * 2007-11-21 2011-02-10 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アルキン類及び１，３−双極子機能性化合物とアルキン類を反応させる方法
JP2015525575A (ja) * 2012-08-08 2015-09-07 アプライズ バイオ， インコーポレイテッド 細胞中の複数のエピトープを同定するためのダイナミックレンジを高めること
EP2974744A1 (en) * 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., vol. 26, JPN6025016722, 2015, pages 257 - 261, ISSN: 0005730754 *
CHEM COMMUN., vol. 54, JPN6025016723, 2018, pages 7338 - 7341, ISSN: 0005730753 *

Also Published As

Publication number Publication date
AR122020A1 (es) 2022-08-03
EP4146665A1 (en) 2023-03-15
TW202207988A (zh) 2022-03-01
US20230192760A1 (en) 2023-06-22
WO2021226247A1 (en) 2021-11-11
CN115551875A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
US11753669B2 (en) Lysine conjugated immunoglobulins
US20230192760A1 (en) Systems and methods for tyrosinase-mediated site-specific protein conjugation
US11236386B2 (en) Method for labeling of aldehyde containing target molecules
HK40078127A (en) Systems and methods for tyrosinase-mediated site-specific protein conjugation
WO2023141855A1 (en) Protein conjugates with multiple payloads and methods for making the same
EP4153619A2 (en) Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
WO2025181697A1 (en) Bifunctional degraders of anti-pla2r antibody
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
US20220072148A1 (en) Novel Methionine Containing Antibodies for Conjugation of Agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251113